Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 383

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 8
Chunk 383
---
    Former President, Chief Executive Officer   and Interim Chief Financial Officer

    2023

    589,600

    178,380

    255,923

    160,460

    -

    $
     
    1,184,363

(1)Amounts in this column for 2023 represent discretionary annual incentive bonuses earned for performance in fiscal 2023, which were paid in 2024.  Discretionary annual bonuses earned by Dr. Bianco and Mr. Dearborn for performance in fiscal 2024, if any, have not been determined or calculated as of the date of the filing of this Annual Report and are expected to be determined during the 60-day period following the date of the filing of this Annual Report, whereupon the determination of any such bonuses will be reported on Form 8-K. For more information regarding the annual bonuses, see “—Narrative Disclosure to Summary Compensation Table — Annual Bonuses” below.

(2)Amounts in this column represent the aggregate grant date fair value of stock options awarded during 2024 and 2023, computed in accordance with FASB Accounting Standards Codification Topic 718. For more information regarding the assumptions used in this calculation, see Note 10 to our financial statements included in this Annual Report.

(3)Amounts in this column represent life insurance premiums paid by us on behalf of Dr. Bianco, Mr. Dearborn and Mr. Yamashita. For more information regarding other compensation awarded or paid to the NEOs, see “— Narrative Disclosure to Summary Compensation Table — Other Compensation” below.

(4)Mr. Yamashita ceased serving as an officer as of December 16, 2024.

(5)Mr. Hoffman, our former President, Chief Executive Officer and Interim Chief Financial Officer, and us were parties to a certain Executive Employment Agreement dated November 8, 2021 (the “Hoffman Employment Agreement”). On October 4, 2024, prior to the completion of the Kintara Merger, we entered into an amendment to the Hoffman Employment Agreement (the “Hoffman Amendment”), pursuant to which, all outstanding stock options previously granted to Mr. Hoffman vested in full on October 4, 2024 in exchange for Mr. Hoffman agreeing to extend the non-competition restrictions of the Hoffman Employment Agreement for a period of twelve months following the date that his employment terminates. Mr. Hoffman’s employment was terminated on October